Skip to main content
In-Vitro Research Only
Sign in

B7-33: The Single-Chain Relaxin Analogue for Fibrosis Research

The Scientific Advisory Board24th Jul 2026

B7-33: The Single-Chain Relaxin Analogue for Fibrosis Research
AT A GLANCE · KEY RESEARCH SUMMARY

What You Need to Know About B7-33: The Single-Chain Relaxin Analogue for Fibrosis Research

Primary Focus
Connective tissue remodelling, RXFP1 receptor signalling, and extracellular matrix turnover in laboratory models of organ fibrosis.
Molecular Profile
A synthetic 27-amino-acid single-chain peptide analogue derived from the B-chain of human relaxin-2, featuring an added C-terminal hexapeptide (KRSLGS) that improves solubility.
Fridge Storage
2°C–8°C (12–24 Months)
Quality Standard
99%+ HPLC Verified
  • Researchers investigate B7-33 because native two-chain human relaxin-2 is difficult and expensive to synthesise, whereas this single-chain analogue is far simpler to produce for laboratory work.
  • It binds to the relaxin family peptide receptor 1 (RXFP1) and triggers a biased signalling pathway that favours pERK1/2 activation over cyclic AMP (cAMP) accumulation.
  • This selective signalling encourages cells to produce matrix metalloproteinases (MMPs), which are natural enzymes that break down excess collagen and stiff scar tissue.
  • In published preclinical models of heart, lung, and kidney scarring, B7-33 reduced excess collagen buildup without triggering the unwanted tumour-promoting signals seen with native relaxin.

How B7-33 Reshapes Tissue Remodelling and Collagen Balance

B7-33 is a laboratory-made, single-chain version of the natural hormone relaxin-2 that selectively tells cells to break down excess scar tissue. In published studies, it activates the relaxin family peptide receptor 1 (RXFP1) to boost matrix-clearing enzymes without triggering unwanted cell growth signals.

To understand why researchers care so much about B7-33: The Single-Chain Relaxin Analogue for Fibrosis Research, it helps to look at how the body handles wear and tear. When organs or blood vessels experience ongoing stress, specialized cells called fibroblasts go into overdrive. They lay down thick sheets of collagen that stiffen the surrounding structure. Natural human relaxin-2 (often called H2 relaxin) acts as a natural brake on this stiffening process, keeping tissues supple and elastic.

However, natural relaxin-2 has two separate peptide chains linked by three sulfur bridges. That two-chain shape makes it tricky and expensive to produce in a laboratory. Worse, natural relaxin-2 turns on two different internal switches at the same time when it docks with the RXFP1 receptor: the pERK pathway and the cAMP pathway. While pERK signalling encourages healthy tissue remodelling, too much cAMP signalling over long periods can speed up unwanted blood vessel growth or help abnormal cells multiply in certain tumour models.

Researchers at the Florey Institute solved both problems in 2016 by isolating just the active B-chain of relaxin and tweaking its soluble tail. The result is B7-33. Because it is a single linear chain of twenty-seven amino acids without any sulfur bridges, chemists can build it cleanly at a fraction of the cost.

More importantly, B7-33 shows what scientists call pathway selectivity. When it binds to RXFP1 on fibroblasts, it strongly flips the pERK1/2 switch while leaving the cAMP switch mostly quiet. That pERK signal travels to the cell nucleus and ramps up the production of matrix metalloproteinase-2 (MMP-2). Think of MMP-2 as a targeted cleanup enzyme that dissolves stubborn, cross-linked collagen fibres, allowing stiffened areas in heart, lung, and kidney models to regain normal elasticity and mechanical recovery.

RELATED UK CATALOGUE

B7-33 is not stocked as its own vial. For relaxin-receptor and fibrosis research, the closest stocked materials are the BPC-157 & TB-500 blend and GHK-Cu.

Browse Full UK Peptide Catalogue →

What Preclinical Models Show From Early Signalling to Later Changes

When scientists introduce B7-33 into cell cultures or preclinical models, the biological response unfolds in two distinct phases: rapid intracellular signalling followed by slower, physical changes to the extracellular matrix. Separating these two stages helps investigators set realistic observation windows for their experiments.

In the first phase, which happens within minutes of exposure in a Petri dish, B7-33 binds to the RXFP1 receptor on the outer surface of fibroblasts and endothelial cells. Laboratory assays measuring phosphorylation show that pERK1/2 levels spike within five to fifteen minutes. During this early window, cAMP levels remain nearly flat compared to tests run with full-length H2 relaxin. Within six to twenty-four hours, this early pERK signal translates into higher messenger RNA expression for MMP-2, alongside a measurable drop in transforming growth factor-beta 1 (TGF-beta 1) activity. Because TGF-beta 1 is the main chemical signal that tells fibroblasts to transform into scar-producing myofibroblasts, quieting it down early stops fresh collagen from piling up.

The second phase—actual structural tissue remodelling—takes days or weeks to show up under a microscope. In published rodent models of heart and kidney stiffening, researchers typically run protocols lasting between seven and twenty-eight days. Over the first week, elevated MMP-2 enzymes begin chewing through existing type I and type III collagen deposits. By week two to week four, histological staining in these preclinical models consistently shows thinner collagen bundles, less interstitial scarring, and better organ flexibility.

In vascular models, researchers also observe rapid endothelial relaxation within hours, driven by nitric oxide release, followed by durable improvements in arterial compliance over multi-week timelines. Another practical finding from these timelines is that B7-33 resists breakdown by natural blood enzymes slightly differently than native relaxin, though researchers sometimes attach a fatty acid or albumin-binding tag if they want to extend its active window in multi-week studies. Across all published studies, the pattern holds steady: biochemical switches flip in minutes, enzyme levels shift within a day, and visible collagen clearance requires two to four weeks of consistent protocol exposure.

Key Study Insight: Unlike native two-chain relaxin-2, single-chain B7-33 selectively activates the pERK1/2 pathway over cAMP at the RXFP1 receptor. Published preclinical models show this targeted signalling boosts collagen-clearing MMP-2 enzymes while avoiding unwanted cell proliferation signals.

B7-33 vs Native Human Relaxin-2 (H2 Relaxin) in Laboratory Models

FeatureB7-33 (Single-Chain Analogue)H2 Relaxin (Native Two-Chain Peptide)
Molecular StructureSingle peptide chain of 27 amino acids with no disulphide bridgesTwo peptide chains (A and B) linked by three complex disulphide bonds
Ease of SynthesisHigh yield and straightforward solid-phase peptide synthesisLow yield, multi-step synthesis requiring complex chain folding
Primary Receptor TargetRXFP1 (functionally selective / biased agonist)RXFP1 (full agonist across multiple pathways)
Dominant Signalling PathwayStrongly favours pERK1/2 signalling over cAMP productionActivates both cAMP and pERK1/2 pathways strongly
Matrix Remodelling ActivityStimulates MMP-2 expression to degrade excess collagen in fibroblast modelsStimulates MMP expression and broad vascular and reproductive tissue changes
Prostate Tumour Growth in Rodent ModelsDid not promote tumour growth at tested concentrations in published studiesAssociated with increased tumour vascularisation and growth via cAMP signalling

Pairing B7-33 With Complementary Sequences in Laboratory Protocols

In laboratory settings, fibrosis rarely happens in isolation. Stiffened tissue almost always goes hand in hand with local inflammation, sluggish cellular energy production, and oxidative stress. Because B7-33 focuses very specifically on the RXFP1-pERK-MMP-2 pathway to clear excess collagen, investigators frequently design multi-peptide protocols that pair it with compounds targeting those other parallel pathways.

A popular pairing in structural recovery studies combines B7-33 with BPC-157 or TB-500 (a synthetic fraction of thymosin beta-4). While B7-33 tells myofibroblasts to slow down collagen dumping and turn up MMP-2 cleanup enzymes, TB-500 helps organise actin filaments so healthy cells can migrate into the remodelled space. Meanwhile, BPC-157 supports micro-vessel formation and calms local inflammatory cytokines. Studied side by side, they allow researchers to watch how clearing old matrix proteins interacts with fresh structural regeneration.

Another growing area of investigation looks at how cellular energy affects tissue stiffness. Fibrotic organs often suffer from tired mitochondria that cannot produce enough ATP to maintain normal cell function. To explore this connection, researchers may run parallel assays using slu pp 332, a small-molecule estrogen-related receptor (ERR) agonist studied for boosting mitochondrial respiration and fatty acid oxidation. When cells have a steady energy supply alongside RXFP1 activation, models of cardiac and renal stress show clearer recovery markers than when either pathway is studied alone.

Researchers also examine how neuro-immune stress signals influence peripheral tissue stiffening. Chronic stress hormones can ramp up systemic inflammation, which feeds right back into TGF-beta 1 activation. In models examining the link between central stress signalling and peripheral markers, investigators sometimes include selank 5mg in their comparative panels to observe how modulating GABAergic and cytokine pathways alters downstream fibrotic responses. Finally, pairing B7-33 with GHK-Cu (a naturally occurring copper-binding tripeptide) is common in skin and connective tissue cultures, as both sequences regulate metalloproteinases and help balance the ratio between collagen breakdown and fresh elastin synthesis.

Why Analytical Grade Purity and Cold Storage Matter for B7-33

Because B7-33 is a twenty-seven-amino-acid linear peptide that relies on a very specific folding shape at its tail end to trigger the RXFP1 receptor, the quality of the raw material in the vial directly controls whether an experiment succeeds or fails. If a batch contains truncated sequences—short, incomplete chains left over from sloppy synthesis—those fragments can sit on the RXFP1 receptor without activating pERK, blocking the real peptide from doing its job.

To avoid muddied data, research laboratories look for B7-33 verified at 99% or higher purity via High-Performance Liquid Chromatography (HPLC) and confirmed by Mass Spectrometry (MS). High-grade synthesis also includes thorough trifluoroacetic acid (TFA) removal. TFA is a harsh acid used to cleave peptides from their solid resin during manufacturing. If excess TFA salts remain trapped in the freeze-dried powder, they lower the pH of the liquid sample and can damage delicate fibroblast cultures on contact, creating false toxicity readouts that have nothing to do with B7-33 itself.

Proper storage is just as important for keeping the single-chain structure intact. Before mixing, lyophilised B7-33 powder stays stable when kept in a dark freezer at minus 20°C or a standard laboratory fridge between 2°C and 8°C, away from bright light and moisture. When a protocol calls for dissolving the powder, technicians let the vial warm to room temperature first to stop condensation from forming inside, then gently introduce a sterile bacteriostatic reconstitution solution down the glass wall.

Swirling the vial softly rather than shaking it prevents physical shearing of the peptide bonds. Once dissolved into liquid form, B7-33 should be stored strictly between 2°C and 8°C and used within its validated stability window, or split into single-use aliquots and frozen to avoid repeated freeze-thaw cycles that degrade receptor binding strength.

Frequently Asked Questions

Why is B7-33 searched so frequently in fibrosis research?

B7-33 is heavily searched because it offers a simpler, single-chain alternative to natural relaxin for studying scar tissue reduction. In laboratory models, researchers observe that it selectively triggers beneficial cellular signalling pathways to support tissue remodelling without activating the secondary pathways that cause unwanted cell growth.

What is the typical timeline observed in B7-33 preclinical studies?

In published studies, researchers typically observe initial changes in cellular signalling within minutes, while measurable tissue remodelling takes between two and four weeks. The exact timeline depends on the specific laboratory model and the measured level applied to the tissue samples being analysed.

Can B7-33 be combined with other peptides in laboratory models?

Yes, researchers occasionally combine B7-33 with other compounds like BPC-157 or TB-500 in preclinical models to analyse overlapping tissue recovery pathways. However, scientists usually test B7-33 alone first to clearly characterise its isolated effects on collagen turnover before introducing a second research compound.

How should B7-33 be stored to maintain high purity?

Unmixed B7-33 powder should be stored in a freezer at minus 20 degrees Celsius to keep its purity above 99 percent. Once mixed with a bacteriostatic reconstitution solution for laboratory work, it must be kept in a fridge between 2 and 8 degrees Celsius and used within four weeks.

Bibliography

  • Hossain MA, Kocan M, Yao ST, et al. A single-chain derivative of the relaxin hormone is a functionally selective agonist of the G protein-coupled receptor, RXFP1. Chemical Science. 2016;7(6):3805-3819. View published research
  • Marshall SA, O'Sullivan K, Ng HH, et al. B7-33 replicates the vasoprotective functions of human relaxin-2 in rat and mouse vasculature. Journal of Hypertension. 2017;35(11):2226-2236. View published research
  • Devarakonda T, Mauro AG, Guzman G, et al. B7-33, a functionally selective relaxin receptor 1 agonist, attenuates myocardial infarction-related adverse cardiac remodeling in mice. Journal of the American Heart Association. 2020;9(8):e015748. View published research
  • Praveen P, Kocan M, Valkovic AL, et al. Single-chain peptide agonists of the relaxin receptors RXFP1 and RXFP2. Molecular and Cellular Endocrinology. 2019;487:34-39. View published research
  • Samuel CS, Royce SG, Hewitson TD, Denton KM, Cooney TE, Bennett RG. Anti-fibrotic actions of relaxin. British Journal of Pharmacology. 2017;174(10):962-976. View published research

⚠️ Research Use Only Disclaimer: All peptides and compounds are sold strictly for in-vitro laboratory research purposes only. Not intended for human or veterinary use, not a dietary supplement, and not approved to diagnose, treat, cure, or prevent any disease or condition. For use by qualified researchers in suitably equipped laboratory environments only. Amino Peptides Ltd operates in full compliance with UK MHRA regulations and applicable EU research chemical guidelines.